Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes
Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
The aim is to test in T2DM patients, whether, compared to placebo, 12 weeks of SGLT-2
inhibitor improves post-absorptive, post-insulin infusion or postprandial insulin action to
enhance Cardiac Muscle vascular function and whether changes correlate with improved GV or
postprandial hyperglycemia